Our broad portfolio of molecular assays yields informative data from cfDNA and cfRNA samples, aiding in host immune response evaluation and therapeutic monitoring biomarker identification.
Our scientific expertise and dedicated teams ensure:
- Consistency
- Timeliness
- Reliability on our robust platforms
- Accurate data analysis reporting
- Compliance with rigorous regulatory standards such as CLIA, GLP, and MD, RI, PA, CA licenses and permits
All of our assays are processed in our US based laboratories.
Clinical trial support
To expedite oncology studies and provide deeper insights into patients’ response to new therapies, we provide a range of targeted and broad NGS panels.
Broad Panel Assays
Liquid Trace and Profile Plus Technology*
Our approach provides high sensitivity and specificity across a large set of genes. Our RNA capabilities go beyond fusion detection to include analyzing exon skipping, alternative splicing and gene expression.
Targeted Panel Assays
Targeted Panel Assays
Detecting low frequency somatic variants requires ultrasensitive liquid biopsy approaches. Our targeted approach balances the primary need for high sensitivity with the breadth of genomic coverage, providing confidence that somatic variants can be detected even at exceedingly low concentrations.
cfHPV DNA Assay
HPV-SEQ
With the ability to reliably and consistently detect as low as 2 copies of cfHPV-DNA, HPV-SEQ makes a powerful tool for surveillance and monitoring during development of cancer therapies for HPV driven cancers.
Ultra-sensitive assay capabilities
Plasma-SeqSensei™ Kits
Currently only available in EMEA region
Plasma-SeqSensei™ kits provide narrow panels with ultra-high sensitivity down to 0.06% mutant allele fractions (MAF) and absolute limit detection of 6 mutant molecules (MM) which is important for the clinical research purpose such as response monitoring, recurrence monitoring, and minimal residual disease detection.
Ultra-high sensitivity down to 0.06% mutant allele fractions (MAF) and absolute limit detection of 6 mutant molecules (MM)